Navigation Links
IP-K extends research deal with Novartis Institute for Tropical Diseases

Dec. 03, 2010, Seoul, S. Korea Institut Pasteur Korea (IP-K) has signed an agreements to continue to mine the chemical compound collection of Novartis Institute for Tropical Diseases (NITD) of Singapore for new drug candidates.

IP-K's PhenomicScreen is a high-throughput, high-content visual screening platform that is ideally suited to identifying lead compounds. Over the past year, PhenomicScreen has been used to search for promising drugs within NITD's chemical compound collection. That deal has now been extended by two years to allow a further exploration of their chemical library.

Dr. Pablo Bifani, Project Team Head at NITD, welcomed his institute's new contract, noting that "The scientific approach we are taking with IP-K is greatly facilitating the selection of candidate compounds for further drug development."

IP-K's Dr. Jonathan Cechetto describes the advantages of PhenomicScreen as being that "The process selects novel targets, and only those which are functionally significant in the disease process". Dr. Priscille Brodin of IP-K adds that "The phenotypic approach does not rely on a predefined target, but rather simultaneously selects both chemical compounds and an unknown cellular target solely by the clearly discernible effect on the disease model".

Center Director of Core Technologies of Institut Pasteur Korea Dr. Veronica Soloveva said that "We are proud to be working with NITD in the fight against infectious diseases". Soloveva is satisfied that the agreement is a vindication of the institute's innovative approach to drug discovery. "Our PhenomicScreen technology is proven to increase the accuracy and speed of drug discovery," she says.


Contact: Jean Kim
Institut Pasteur Korea

Page: 1

Related biology news :

1. GenWay Biotech extends the You Test You program overseas
2. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
3. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
4. $5.1 million Army-Md. alliance speeds university research to market
5. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
6. Researchers describe first functioning lipidome of mouse macrophage
7. U of M researcher helps unlock 30 new genes responsible for early onset puberty
8. Stroke research takes 2 steps forward
9. Researchers find link between sugar, diabetes and aggression
10. Arjun Deb awarded Louis N. and Arnold M. Katz Basic Science Research Prize
11. Snakes on a rope: Researchers take a unique look at the climbing abilities of boa constrictors
Post Your Comments:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology: